Company Presentation May 06, 2024 Company Presentation Other Presentations April 9, 2024 AACR 2024: Development of Tumor-restricted IL-12 With Antigen-dependent Expression and Localized IL-12 Activity April 7, 2024 AACR 2024: Preclinical ROR1-Targeted CAR T-Cell Product Incorporating Four Novel Reprogramming Technologies Designed for Effective Cell Therapy for Solid Tumors November 4, 2023 SITC 2023: Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors November 4, 2023 SITC 2023: Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) November 3, 2023 SITC 2023: Epi-R P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time November 3, 2023 SITC 2023: Rejuvenation of tumor-infiltrating lymphocytes (TIL) through Partial Reprogramming November 3, 2023 SITC 2023: Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies November 3, 2023 SITC 2023: Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors June 14, 2023 Rejuvenation: Improving T-cell Antitumor Properties Through Partial Reprogramming May 17, 2023 Preclinical Development of LYL119, a ROR1-Targeted CAR T-Cell Product Candidate Incorporating Four Novel T-Cell Reprogramming Technologies to Overcome Barriers to Effective Cell Therapy for Solid Tumors Pagination Current page 1 Page 2 Next page next › Last page last »
